Evaluation of Inflammatory Markers in LARC Patients

Hospital Pedro Hispano245 enrolled

Overview

Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis. Methods: Retrospective analysis of 245 LARC patients diagnosed between January 2010 and December 2022, who underwent neoadjuvant chemoradiotherapy and surgery at two centers. A Cox regression and Kaplan-Meier analysis were performed.

Study Type

OBSERVATIONAL

Enrollment

245

Conditions

Locally Advanced Rectal Cancer

Interventions

Inflammatory markersDIAGNOSTIC_TEST

analysis of inflammatory scores

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients diagnosed pathologically with rectal adenocarcinomas, located within 12cm from the anal verge (measured by MRI), clinically staged T3-4 and/or N+ and treated with neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery Exclusion Criteria: * evidence of distant metastasis at diagnosis, emergent or palliative surgery, local excision or "watch and wait" approach and evidence of inflammatory or hematological disorders

Outcomes

Primary Outcomes

Overall survival Disease-free survival

Time frame: 5 years

Secondary Outcomes

Pathological response through Ryan Tumor Regression Grade

TRG 1-5; 1- no viable cancer cells; 5- no fibrosis, with extensive residual disease

Time frame: at study completion, average of 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.